Skip to main content

Table 1 Demographic characteristics in infectious disease and hematological disease patients with or without hypofibrinogenemia

From: Hypofibrinogenemia is associated with a high degree of risk in infectious diseases: a post-hoc analysis of post-marketing surveillance of patients with disseminated intravascular coagulation treated with thrombomodulin alfa

 

Infectious disease

Hematological disease

Fibrinogen, g/L

≥1.5

< 1.5

p-value

≥1.5

< 1.5

p-value

Age, years

1865

71 (60–79)

215

70 (53–79)

0.1094

809

61 (43–70)

311

63 (41–73)

0.0578

Male

1868

1096 (58.7)

215

109 (50.7)

0.0249

809

506 (62.5)

312

165 (52.9)

0.0045

Body weight, kg

1861

50 (40–60)

215

53 (45–62)

0.0005

808.

55 (48.4–64)

312

55 (48.2–63.8)

0.7995

SOFA score

1164

10 (7–13)

118

11 (8–15)

0.0144

JMHW DIC score

1081

6 (5–7)

104

9 (7–10)

< 0.0001

551

4 (3–5)

226

6 (5–7)

< 0.0001

ISTH DIC score

580

4 (4–5)

54

5 (4–7)

0.0002

209

5 (4–6)

81

6 (5–7)

< 0.0001

JAAM DIC score

1198

5 (4–7)

119

6 (5–8)

0.0005

Pre-administration

1868

 

215

  

809

 

312

  

AT concentrate

 

364 (19.5)

 

27 (12.6)

0.0138

 

62 (7.7)

 

13 (4.2)

0.0357

Gabexate mesylate

 

343 (18.4)

 

42 (19.5)

0.6748

 

61 (7.5)

 

29 (9.3)

0.3326

Nafamostat mesylate

 

175 (9.4)

 

12 (5.6)

0.0658

 

29 (3.4)

 

12 (3.8)

0.8344

Unfractionated heparin

 

91 (4.9)

 

6 (2.8)

0.1703

 

29 (2.4)

 

7 (2.2)

0.2537

LMWH

 

34 (1.8)

 

5 (2.3)

0.6046

 

65 (8.0)

 

10 (3.2)

0.0037

Danaparoid sodium

 

66 (3.5)

 

8 (3.7)

0.8880

 

31 (3.8)

 

20 (6.4)

0.0634

Comorbidities

1868

 

215

  

809

 

312

  

Bleeding symptoms

 

234 (12.5)

 

54 (25.1)

< 0.0001

 

225 (27.8)

 

144 (46.2)

< 0.0001

Organ symptoms

 

861 (46.1)

 

116 (54.0)

0.0292

 

221 (27.3)

 

71 (22.8)

0.1189

  1. Data are given as n (%) or median (IQR)
  2. DIC, disseminated intravascular coagulation; AT, antithrombin; LMWH, low molecular weight heparin; SOFA, sequential organ failure assessment;
  3. JMHW, Japanese Ministry of Health and Welfare; ISTH, International Society of Thrombosis Haemostasis; JAAM, Japanese Association for Acute Medicine